(Q26765210)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

title

Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

main subject

hepatocellular carcinoma

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Sara Marinelli

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

author name string

Giulia Negrini

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Saverio Menetti

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Francesca Benevento

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

Luigi Bolondi

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

language of work or name

English

0 references

publication date

1 March 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

Therapeutic Advances in Gastroenterology

9 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

page(s)

240-249

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

Sorafenib: from literature to clinical practice

9 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Sorafenib in advanced hepatocellular carcinoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Management of hepatocellular carcinoma

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Mechanisms of adverse effects of anti-VEGF therapy for cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Cutaneous side-effects of kinase inhibitors and blocking antibodies

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4749854

Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.

28 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15618129

Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15618129

Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15618129

Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15618129

Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15618129

Pancreatic atrophy--a new late toxic effect of sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15618129

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15618129

Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15618129

Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15618129

Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15618129

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15618129

Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15618129

Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15618129

Field-practice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1756283X15618129

Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib

1 reference

12 December 2020

Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma

1 reference

12 December 2020

VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study

1 reference

12 December 2020

Sorafenib-induced diarrhea and hypophosphatemia: mechanisms and therapeutic implications

1 reference

12 December 2020

Identifiers

DOI

10.1177/1756283X15618129

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26929785%20AND%20SRC:MED&resulttype=core&format=json

9 March 2020

PubMed publication ID

26929785

1 reference